Next-Generation Antibody Market Forecast to 2028

Report Code : TIPRE00006412 | Region : Global | Industry : Medical Device | Published Date : 07/Jan/2022
Next-Generation Antibody Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Area (Oncology and Autoimmune or Inflammatory) and Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Fc Engineered Antibodies, Antibody Fragments and Antibody-Like Proteins, and Biosimilar Antibody Products

The global next-generation antibody market is expected to reach US$ 12,050.13 million by 2028 from US$ 5,428.41 million in 2021; it is estimated to grow at a CAGR of 11.9% from 2021 to 2028.

Factors such as the increasing prevalence of cancer and growing demand for next-generation antibody therapeutics are boosting the market growth. However, complications associated with the manufacturing and approvals hamper the growth of the next-generation antibody market.

Next-generation antibodies are designed to be more specific and often more potent than traditional monoclonal antibodies. Next-generation antibody strategies are required to engineer a useful therapeutic combining antibody, payload, linker, and conjugation method while ensuring stability, targeted delivery, and limited off-target effects.

The next-generation antibody market is segmented on the basis of therapeutic area, technology, and geography. Based on therapeutic area, the market is bifurcated into oncology and

autoimmune or inflammatory. The oncology segment held a larger share of the market in 2021. Moreover, the same segment is expected to register a higher CAGR during the forecast period. Based on technology, the next-generation antibody market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. The antibody-drug conjugates segment is expected to hold the largest share of the market in the coming years. However, the bispecific antibodies segment is expected to register the highest CAGR from 2021 to 2028 due to the rise in usage of bispecific antibodies in the treatment of various diseases across the globe.

Globocan statistics, World Health Organization (WHO), International Agency for Research on Cancer (IARC), and Organization for Economic Co-operation and Development (OECD) are among the primary and secondary sources referred to while preparing the report on the next-generation antibody market.

The List of Companies - Next-generation Antibody Market

1. F. HOFFMANN-LA ROCHE LTD.

2. Kyowa Kirin Co., Ltd.

3. Seagen Inc.

4. ImmunoGen, Inc.

5. Takeda Pharmaceutical Company Limited

6. Amgen Inc.

7. Pfizer Inc.

8. Catalent Inc

9. AstraZeneca

10. Xencor

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Next-generation Antibody Market – By Therapeutic Area

1.3.2 Global Next-generation Antibody Market – By Technology

1.3.3 Global Next-generation Antibody Market – By Geography

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Next-generation Antibody Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific PEST Analysis

4.2.4 Middle East and Africa PEST Analysis

4.2.5 South And Central America PEST Analysis

4.3 Experts Opinion

5. Next-generation Antibody Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Prevalence of Cancer

5.1.2 Growing Demand for Next-Generation Antibody Therapeutics

5.2 Market Restraints

5.2.1 Complications Associated with Manufacturing and Approvals

5.3 Market Opportunities

5.3.1 Proliferation of Biotechnology Industry in Developing Regions

5.4 Future Trends

5.4.1 Developments in Next-Generation Antibodies

5.5 Impact Analysis

6. Next-generation Antibody Market– Global Analysis

6.1 Global Next-generation Antibody Market Revenue Forecast and Analysis

6.2 Global Next-generation Antibody Market, By Geography - Forecast and Analysis

6.3 Market Positioning of Key Players

7. Global Next-generation Antibody Market Revenue and Forecasts To 2028– by Therapeutic Area

7.1 Overview

7.2 Global Next-generation Antibody Market, By Therapeutic Area, 2021 & 2028 (%)

7.3 Oncology

7.3.1 Overview

7.3.2 Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

7.4 Autoimmune or Inflammatory

7.4.1 Overview

7.4.2 Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

8. Next-generation Antibody Market Revenue and Forecasts To 2028 – Technology

8.1 Overview

8.2 Global Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)

8.3 Antibody-drug conjugates

8.3.1 Overview

8.3.2 Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

8.4 Bispecific antibodies

8.4.1 Overview

8.4.2 Bispecific antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

8.5 Fc engineered antibodies

8.5.1 Overview

8.5.2 Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

8.6 Antibody fragments and antibody-like proteins

8.6.1 Overview

8.6.2 Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

8.7 Biosimilar antibody products

8.7.1 Overview

8.7.2 Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)

9. Next-generation Antibody Market Revenue and Forecasts to 2028 – Geographical Analysis

9.1 North America: Next-generation Antibody Market

9.1.1 Overview

9.1.2 North America: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.3 North America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)

9.1.4 North America: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)

9.1.5 North America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)

9.1.5.1 US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.1.1 Overview

9.1.5.1.2 US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.1.3 US: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)

9.1.5.1.4 US: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)

9.1.5.2 Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.2.1 Overview

9.1.5.2.2 Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.2.3 Canada: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)

9.1.5.2.4 Canada: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)

9.1.5.3 Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.3.1 Overview

9.1.5.3.2 Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.3.3 Mexico: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)

9.1.5.3.4 Mexico: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)

9.2 Europe: Next-generation Antibody Market

9.2.1 Overview

9.2.2 Europe: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.3 Europe: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

9.2.4 Europe: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

9.2.5 Europe: Next-generation Antibody Market, by Country, 2021 & 2028 (%)

9.2.5.1 Germany: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.1.1 Overview

9.2.5.1.2 Germany: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.1.3 Germany: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

9.2.5.1.4 Germany: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

9.2.5.2 France: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.2.1 Overview

9.2.5.2.2 France: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.2.3 France: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

9.2.5.2.4 France: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

9.2.5.3 UK: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.3.1 Overview

9.2.5.3.2 UK: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.3.3 UK: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

9.2.5.3.4 UK: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

9.2.5.4 Italy: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.4.1 Overview

9.2.5.4.2 Italy: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.4.3 Italy: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

9.2.5.4.4 Italy: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

9.2.5.5 Spain: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.5.1 Overview

9.2.5.5.2 Spain: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.5.3 Spain: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

9.2.5.5.4 Spain: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

9.2.5.6 Rest of Europe: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.6.1 Overview

9.2.5.6.2 Rest of Europe: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.6.3 Rest of Europe: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

9.2.5.6.4 Rest of Europe: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

9.3 Asia Pacific Next-generation Antibody Market Revenue and Forecasts To 2028

9.3.1 Overview

9.3.2 Asia Pacific Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.3 Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.3.4 Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

9.3.5 Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)

9.3.5.1 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.1.1 Overview

9.3.5.1.2 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.1.3 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.3.5.1.4 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

9.3.5.2 China: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.2.1 Overview

9.3.5.2.2 China: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.2.3 China: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.3.5.2.4 China: Next-generation Antibody Market Revenue and Forecasts to 2028, by Technology (US$ Million)

9.3.5.3 India Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.3.1 Overview

9.3.5.3.2 India: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.3.3 India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.3.5.3.4 India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

9.3.5.4 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.4.1 Overview

9.3.5.4.2 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.4.3 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.3.5.4.4 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

9.3.5.5 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.5.1 Overview

9.3.5.5.2 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.5.3 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.3.5.5.4 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Application (US$ Million)

9.3.5.6 Rest of Asia Pacific: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.3.5.6.1 Overview

9.3.5.6.2 Rest of Asia Pacific: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.3.5.6.3 Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.3.5.6.4 Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

9.4 Middle East & Africa Next-generation Antibody Market Revenue and Forecasts To 2028

9.4.1 Overview

9.4.2 Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.4.3 Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.4.4 Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

9.4.5 Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)

9.4.5.1 UAE: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.4.5.1.1 Overview

9.4.5.1.2 UAE: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.4.5.1.3 UAE: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.4.5.1.4 UAE: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)

9.4.5.2 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.4.5.2.1 Overview

9.4.5.2.2 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.4.5.2.3 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.4.5.2.4 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)

9.4.5.3 South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.4.5.3.1 Overview

9.4.5.3.2 South Africa Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.4.5.3.3 South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.4.5.3.4 South Africa: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)

9.4.5.4 Rest of Middle East and Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.4.5.4.1 Overview

9.4.5.4.2 Rest of Middle East and Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)

9.4.5.4.3 Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

9.4.5.4.4 Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)

9.5 South and Central America Next-generation Antibody Market Revenue and Forecasts To 2028

9.5.1 Overview

9.5.2 South and Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)

9.5.3 South and Central America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (USD Million)

9.5.4 South and Central America: Next-generation Antibody Market, by Technology, 2019–2028 (USD Million)

9.5.5 South and Central America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)

9.5.5.1 Brazil: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.1.1 Overview

9.5.5.1.2 Brazil: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.1.3 Brazil: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (USD Million)

9.5.5.1.4 Brazil: Next-generation Antibody Market, by Technology, 2019–2028 (USD Million)

9.5.5.2 Argentina: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.2.1 Overview

9.5.5.2.2 Argentina: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.2.3 Argentina: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (USD Million)

9.5.5.2.4 Argentina: Next-generation Antibody Market, by Technology, 2019–2028 (USD Million)

9.5.5.3 Rest of South & Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.3.1 Overview

9.5.5.3.2 Rest of South & Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.3.3 Rest of South & Central America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (USD Million)

9.5.5.3.4 Rest of South & Central America: Next-generation Antibody Market, by Technology, 2019–2028 (USD Million)

10. Impact Of COVID-19 Pandemic on Next-generation Antibody Market

10.1 North America: Impact Assessment of COVID-19 Pandemic

10.2 Europe: Impact Assessment of COVID-19 Pandemic

10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic

10.5 South and Central America: Impact Assessment of COVID-19 Pandemic

11. Next-generation Antibody Market–Industry Landscape

11.1 Overview

11.2 Growth Strategies in the Next-generation Antibody Market (%)

11.3 Organic Developments

11.3.1 Overview

11.4 Inorganic Developments

11.4.1 Overview

12. Company Profiles

12.1 F. HOFFMANN-LA ROCHE LTD.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Kyowa Kirin Co., Ltd.

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Seagen Inc.

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 ImmunoGen, Inc.

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Takeda Pharmaceutical Company Limited

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Amgen Inc.

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Pfizer Inc.

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Catalent Inc

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 AstraZeneca

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

12.10 Xencor

12.10.1 Key Facts

12.10.2 Business Description

12.10.3 Products and Services

12.10.4 Financial Overview

12.10.5 SWOT Analysis

12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

LIST OF TABLES.

Table 1. New Cancer Cases Registered Worldwide, 2020

Table 2. North America Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 3. North America Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 4. US Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 5. US Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 6. Canada: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 7. Canada Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 8. Mexico: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 9. Mexico Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 10. Europe: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 11. Europe: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 12. Germany: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 13. Germany: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 14. France: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 15. France: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 16. UK: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 17. UK: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 18. Italy: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 19. Italy: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 20. Spain: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 21. Spain: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 22. Rest of Europe: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 23. Rest of Europe: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 24. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million).

Table 25. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 26. Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 27. Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 28. China: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 29. China: Next-generation Antibody Market Revenue and Forecasts to 2028, by Technology (US$ Million)

Table 30. India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 31. India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 32. South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 33. South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 34. Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 35. Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Application (US$ Million)

Table 36. Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 37. Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 38. Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million).

Table 39. Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 40. UAE: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 41. UAE: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 42. Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 43. Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 44. South Africa Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 45. South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 46. Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)

Table 47. Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 48. South and Central America: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 49. South and Central America: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 50. Brazil: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 51. Brazil: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 52. Argentina: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 53. Argentina: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 54. Rest of South & Central America: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)

Table 55. Rest of South & Central America: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 56. Organic Developments in the Next-generation Antibody Market

Table 57. Inorganic Developments in the Next-generation Antibody Market

Table 58. Glossary of Terms

The List of Companies - Next-generation Antibody Market

1. F. HOFFMANN-LA ROCHE LTD.

2. Kyowa Kirin Co., Ltd.

3. Seagen Inc.

4. ImmunoGen, Inc.

5. Takeda Pharmaceutical Company Limited

6. Amgen Inc.

7. Pfizer Inc.

8. Catalent Inc

9. AstraZeneca

10. Xencor

Reason To Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the next-generation antibody market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global next-generation antibody market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the next-generation antibody market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Next-Generation Antibody Market Forecast to 2028 )
  • Single User Price $4,550$3,640
  • Site Price $6,550$5,240
  • Enterprise Price $8,550$6,840
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry